sameAs
Physiotherapy interventions for ankylosing spondylitisPhysiotherapy interventions for ankylosing spondylitisA CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritisClinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early diseaseThe changing landscape of biosimilars in rheumatologyEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateUpdating the OMERACT filter: core areas as a basis for defining core outcome setsA reference case for economic evaluations in osteoarthritis: an expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statementUpdating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validityEULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteriaUpdated consensus statement on the use of rituximab in patients with rheumatoid arthritis.Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study GroupReactive arthritis: incidence, triggering agents and clinical presentationTreatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazineEULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.Patient perspective in outcome assessments--perceptions or something more?Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.Data driven attempt to create a clinical algorithm for identification of women with rheumatoid arthritis at high risk of osteoporosis.Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention study.Is there a role for sulphasalazine in axial spondyloarthritis in the era of TNF inhibition? Data from the NOR-DMARD longitudinal observational study.Inconsistent treatment with disease-modifying antirheumatic drugs: a longitudinal data analysisNOR-DMARD data management: implementation of data capture from electronic health records.Body mass index and progressive hand osteoarthritis: data from the Oslo hand osteoarthritis cohort.First step in the development of an ultrasound joint inflammation score for rheumatoid arthritis using a data-driven approach.Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaborationDiscordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMAHealth-related quality of life in women with symptomatic hand osteoarthritis: a comparison with rheumatoid arthritis patients, healthy controls, and normative data.Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration.Translation and performance of the Norwegian SF-36 Health Survey in patients with rheumatoid arthritis. I. Data quality, scaling assumptions, reliability, and construct validity.Lack of association between the chemokine receptor 5 polymorphism CCR5delta32 in rheumatoid arthritis and juvenile idiopathic arthritis.Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis.Obesity and osteoarthritis in knee, hip and/or hand: an epidemiological study in the general population with 10 years follow-up.Perception of improvement in patients with rheumatoid arthritis varies with disease activity levels at baseline.EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.Natural killer (NK) cell activity of peripheral blood, synovial fluid, and synovial tissue lymphocytes from patients with rheumatoid arthritis and juvenile rheumatoid arthritisEULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology.Concurrent evaluation of data quality, reliability and validity of the Australian/Canadian Osteoarthritis Hand Index and the Functional Index for Hand Osteoarthritis.Multidisciplinary and multifaceted outpatient management of patients with osteoarthritis: protocol for a randomised, controlled trial.
P50
Q24242813-54104C0F-85B7-439C-B0FA-89AE3168963BQ24245684-47142608-926A-4F99-943C-D276FCD87819Q24609382-9E390C7C-6495-4456-ABBE-D4F1FE1AE86BQ26753120-B42E72F8-3BDB-4D02-A95D-0F6BF5B4F721Q26766515-3DCF42C3-FC51-4D78-9502-C9AFF4AD080DQ26859134-33F559E6-BE81-4698-ADF2-9384B05A71B3Q26995824-046FAB62-AA1C-4F58-8410-40ACFB3257D1Q27015782-A907DA61-3413-4E80-B465-4A6C0F2CE168Q27021115-407B0046-DC9F-4B65-BFA0-5803E5BB1ACAQ27022415-0B5FC245-50EC-439C-81B9-C61B46B48B8EQ27026582-55527FBE-8227-481F-B980-88BDA87FA112Q27691388-6E9D43F0-3EEC-45F3-8068-6D54D5EA37E6Q28138338-7B56A862-F50C-43DF-85CC-73725CF70C2CQ28251791-9195E68D-E18A-4578-B2E9-7BEAC113EC3AQ28353468-9C5F1DFC-0019-47AF-89AA-1EACC1FCCB0AQ30244903-BCEA727C-E5C5-4542-B686-94E47ED6B894Q30482468-BF8F92FD-E2A6-4DDF-A00D-9A41556FC3A6Q30612910-0E23EB0F-288F-4B3B-8113-C5467B21EE3AQ30614235-314DA1FE-BE63-4DB8-AFB9-B7AB2CD8E885Q30667212-12922AEB-01DE-4ADD-8DDC-0A0CCA95CFDFQ30750448-33E5FD41-87FF-49F4-A0B3-FBB7EBC869DEQ30860792-AA697D7C-4C17-4F1B-B6C4-9C85E3CD3057Q30866962-E4F191BE-41C5-40A7-8A78-BD19D01EA433Q30904816-73EC0E3C-9E1C-4D9E-B9B9-A72294FF44D8Q30974307-84897ED5-A54C-420C-8D10-040BCFF6A5ACQ31046441-24276A06-E43E-402E-B079-E28892709CE2Q31135066-20A4C47D-C5E8-444C-8FE5-FDF214809C8FQ31138492-17E04513-D556-4E67-BC73-8AEBC701203BQ31154802-37EE168A-685F-4247-AA34-4FED6EE03B6CQ31975166-4AFAB8DB-CC8A-4F5B-B44B-32DD7FBA6A15Q33287486-BBF10164-C8A1-46B7-83E5-29B78C209304Q33369384-2969A3EF-A690-4192-81B0-7C4CF7991D44Q33369386-33F66F58-2ED3-46BB-97F1-B7FE698078FCQ33373508-C0B5904C-9828-4453-AC3B-B4FA3A50D087Q33413162-0C91AC7D-F297-47C5-B0E4-B6AAC8CDC9CAQ33505914-60CFB2EF-89A1-4645-A60A-844028FEA979Q33553973-D103A755-A2E5-470D-819D-E2771017F27AQ33595690-9F4D8A8E-97E9-4B68-AE35-1C68625A2C66Q33655026-84CBC772-FA05-427D-BE33-03554FF04633Q33735306-EB5A348A-4FBA-4E24-B207-542164CC2B11
P50
description
Noors onderzoeker
@nl
Norwegian researcher
@en
norsk forsker
@nb
taighdeoir Ioruach
@ga
name
Tore K. Kvien
@ast
Tore K. Kvien
@da
Tore K. Kvien
@de
Tore K. Kvien
@en
Tore K. Kvien
@es
Tore K. Kvien
@fr
Tore K. Kvien
@ga
Tore K. Kvien
@nb
Tore K. Kvien
@nl
Tore K. Kvien
@nn
type
label
Tore K. Kvien
@ast
Tore K. Kvien
@da
Tore K. Kvien
@de
Tore K. Kvien
@en
Tore K. Kvien
@es
Tore K. Kvien
@fr
Tore K. Kvien
@ga
Tore K. Kvien
@nb
Tore K. Kvien
@nl
Tore K. Kvien
@nn
altLabel
Tore K Kvien
@en
Tore Kristian Kvien
@nb
Tore Kvien
@nb
prefLabel
Tore K. Kvien
@ast
Tore K. Kvien
@da
Tore K. Kvien
@de
Tore K. Kvien
@en
Tore K. Kvien
@es
Tore K. Kvien
@fr
Tore K. Kvien
@ga
Tore K. Kvien
@nb
Tore K. Kvien
@nl
Tore K. Kvien
@nn
P1006
P214
P1006
P101
P21
P214
P2287
P27
P31
P496
0000-0002-8441-3093
P569
1949-01-01T00:00:00Z
P734
P7859
viaf-203108274